Clinical Research
Along with normal clinical service, wide range of clinical trials also provided in our center
We are actively recruiting patient to participate in the following clinical trials
Please send referral letter to medicaloncology@hku.hk if interested
Lung Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
MK-7684A-003
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer
MK-7684A (vibostolimab + pembrolizumab)
GS-US-576-6220
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
Sacituzumab Govitecan-hziy (SG)
BA 3011-002
A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor
BA3011
VS
BA3011 +PD-1 inhibitor
475-0708 MT Lung
A Phase 2 Open-label Single-arm Study to Evaluate the Combination of Pembrolizumab, Lenvatinib and Chemotherapy in Non-small Cell Lung Cancer (NSCLC) Harbouring Targetable Mutation and Failed Standard Tyrosine Kinase Inhibitors
Pembrolizumab + Lenvatinib + Pemetrexed + Carboplatin
GS-US-624-6376
(Velocity 01/02)
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients with Lung Cancer
Novel Treatment combination